Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 17;25(20):11149.
doi: 10.3390/ijms252011149.

Rheumatoid Arthritis and COVID-19 at the Intersection of Immunology and Infectious Diseases: A Related PRISMA Systematic Literature Review

Andreea-Iulia Vlădulescu-Trandafir  1   2 , Violeta-Claudia Bojincă  1   3 , Constantin Munteanu  2   4 , Aurelian Anghelescu  2   5 , Cristina Popescu  1   2 , Simona-Isabelle Stoica  2   5 , Sorina Aurelian  1   6 , Andra Bălănescu  1   3 , Cristina Băetu  1   7 , Vlad Ciobanu  8 , Gelu Onose  1   2
Affiliations

Rheumatoid Arthritis and COVID-19 at the Intersection of Immunology and Infectious Diseases: A Related PRISMA Systematic Literature Review

Andreea-Iulia Vlădulescu-Trandafir et al. Int J Mol Sci. .

Abstract

Rheumatoid arthritis (RA) patients face different health challenges when infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) than the general population, due to both their immunocompromised state and the immunosuppressive therapies they receive. This systematic literature review, which follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) paradigm, explores the interactions between RA and SARS-CoV-2 infection, focusing on immunologic issues, disease management, vaccination, and adverse outcomes. In order to obtain the most relevant information, we systematically reviewed the specific literature from 1 January 2021 to 31 December 2023, based on the PRISMA method, by which we eventually selected 35 eligible articles, to which we added other ISI-indexed studies to enrich our results further. Consequently, we performed a funnel analysis to evaluate the potential for publication bias. Firstly, the data collected revealed the impact of the pandemic on RA diagnoses and the fear of face-to-face medical consultations that delayed adequate treatment. Secondly, cardiovascular and metabolic comorbidities increase the risk of prolonged COVID-19 symptoms, hospitalization, and severe COVID-19 outcomes for RA patients. With respect to immunosuppressive treatment used to control RA, it was observed that glucocorticoids (especially high-dose usage) and Rituximab (RTX) predispose the patients to poor SARS-CoV-2 outcomes, as opposed to Baricitinib and interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) inhibitors. COVID-19 vaccination has proven effective and generally safe for RA patients in some studies, although therapies with Methotrexate (MTX), Abatacept (ABA), and RTX have been associated with impaired vaccine immune response. This systematic literature review brings updated and thorough information with respect to the immunological, clinical, and management of a complex immune-mediated inflammatory disease (IMID) like RA in the setting of COVID-19 and underlines the challenges faced by this group of patients. The lessons learned can be extended beyond the pandemic in shaping a more informed and compassionate healthcare system and offering long-term medical care for patients with RA.

Keywords: COVID-19; COVID-19 vaccination; PRISMA systematic literature review; Rituximab; SARS-CoV-2; rheumatoid arthritis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Adapted PRISMA flow diagram (2020), customized for our study.
Figure 2
Figure 2
Funnel plot analysis customized for our study.
See this image and copyright information in PMC

References

    1. Codreanu C., Ionescu R., Predeteanu D., Rezus E., Parvu M., Mogosan C., Popescu C., Rednic S. Recommendations of the Romanian Society of Rheumatology regarding the management of patients with rheumatic diseases in the context of the SARS-CoV-2 pandemic. Rom. J. Rheumatol. 2020;29:101–111. doi: 10.37897/RJR.2020.3.1. - DOI
    1. Trandafir A.I., Onose G., Munteanu C., Băila M., Saglam A.O., Mandu M., Săulescu I., Grădinaru E., Bojincă V.C. Particularities regarding Clinical-biological and Evolutive Parameters of Immune-mediated Rheumatic Diseases in Patients with COVID-19-systematic literature review. Balneo PRM Res. J. 2023;2023:562. doi: 10.12680/balneo.2023.562. - DOI
    1. Kraaijkamp J.J.M., Persoon A., Aurelian S., Bachmann S., Cameron I.D., Choukou M.-A., Dockery F., Eruslanova K., Gordon A.L., Grund S., et al. eHealth in Geriatric Rehabilitation: An International Survey of the Experiences and Needs of Healthcare Professionals. J. Clin. Med. 2023;12:4504. doi: 10.3390/jcm12134504. - DOI - PMC - PubMed
    1. Malek Mahdavi A., Varshochi M., Hajialilo M., Dastgiri S., Khabbazi R., Khabbazi A. Factors associated with COVID-19 and its outcome in patients with rheumatoid arthritis. Clin. Rheumatol. 2021;40:4527. doi: 10.1007/s10067-021-05830-4. - DOI - PMC - PubMed
    1. Bournia V.K., Fragoulis G.E., Mitrou P., Mathioudakis K., Tsolakidis A., Konstantonis G., Tseti I., Vourli G., Tektonidou M.G., Paraskevis D., et al. Different COVID-19 outcomes among systemic rheumatic diseases: A nation-wide cohort study. Rheumatology. 2023;62:1047–1056. doi: 10.1093/rheumatology/keac422. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources